Abstract: In some examples, a multilevel retort assembly. The assembly includes a base defining a base perimeter; and a plurality of shells. Each shell has a diffuser plate support and a perimeter with a substantially similar shape as the base perimeter. The plurality of shells are stacked on each other, mechanically supported by the base, and surround an inner retort volume. The at least one shell of the plurality of shells defines a removable window. The assembly also includes a plurality of diffuser plates, each diffuser plate supported by a corresponding diffuser plate support of the plurality of diffuser plate supports.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: A rotor assembly for a peristaltic pump is provided. Each of a first pair of roller assemblies includes a first roller portion having a first diameter and a second roller portion having a second diameter. The first diameter is larger than the second diameter. Each of a second pair of roller assemblies includes a first roller portion having a first diameter and a second roller portion having a second diameter. The first diameter is smaller than the second diameter. The first and second pairs of roller assemblies are positionable around a circumference of a hub such that the first roller portion of the first pair of roller assemblies is aligned with the first roller portion of the second pair of roller assemblies and the second roller portion of the first pair of roller assemblies is aligned with the second roller portion of the second pair of roller assemblies.

Abstract: A power control system for an aerosol-generating device includes at least one processor and a memory. The memory is coupled to the at least one processor and is configured to store instructions. The at least one processor is configured to execute the instructions to cause the power control system to determine whether a first power to be applied to a heater of the aerosol-generating device exceeds a power threshold, in response to the first power exceeding the power threshold, apply a second power to the heater, and in response to the first power not exceeding the power threshold, apply the first power to the heater. The first power is based on a desired heater temperature. The second power does not exceed the power threshold.

Abstract: A session control system for a device includes at least one processor and a memory coupled to the at least one processor. The memory is configured to store instructions. The at least one processor is configured to execute the instructions to cause the session control system to detect when a session has started, start a session timer, increment a puff variable when an airflow sensor detects that a puff has been taken, monitor the session timer against a time threshold and the puff variable against a puff threshold, and in response to a session threshold being met, end the session. The session timer is configured to measure a length of the session and the puff variable corresponds to a total number of puffs taken.

Abstract: A capsule monitoring system for an aerosol-generating device includes at least one processor and a memory. The memory is coupled to the at least one processor and storing instructions. The at least one processor is configured to execute the instructions to cause the capsule monitoring system to detect a mechanism detection switch of the aerosol-generating device being actuated, apply a first power to a first contact point of the aerosol-generating device, determine a first resistance between the first contact point and a second contact point, determine whether the first resistance is within a resistance operation range, and in response to the first resistance being within of the resistance operation range, display a capsule accepted indicator. The first contact point is configured to contact a heater. The second contact point is configured to contact the heater.

Abstract: A charging system for an aerosol-generating device includes a processor and a memory in communication with the processor and configured to store instructions is provided. The instructions define at least one of a disable mode, an intra-session mode, or an inter-session mode. The processor is configured to execute the instructions to cause the charging system to detect when the device is connected to a charging device; activate a power source charger in response to the connection to the charging device; identify a selected mode; enable or disable a heater of the capsule dependent upon the selected mode; if the heater is enabled, display a first display indicating the connection of the charging device; if the heater is enabled, detect if a session of the aerosol-generating device is ongoing; and if the session is ongoing, enable or suspend charging in response to the identification of the selected mode.

Abstract: A heat-not-burn aerosol-generating device includes a housing that defines a capsule-receiving cavity and a lid fixedly coupled to the housing at a first point and releasably coupleable to the housing at a second point that is different from the first point. The lid is configured to cover the capsule-receiving cavity in a closed position. The lid includes a first retainer and a replaceable mouthpiece coupleable to the lid such that air entering the housing and drawn through the capsule-receiving cavity exits out of the replaceable mouthpiece. The mouthpiece includes a second retainer that is configured to engage with the first retainer so as to releasably secure the replaceable mouthpiece to the lid.

Abstract: A cooldown system for a device includes at least one processor and a memory coupled to the at least one processor. The memory is configured to store instructions. The at least one processor is configured to execute the instructions to cause the cooldown system to detect when a session has ended, activate a cooldown timer to measure a cooldown time, provide an indication of a remaining time of the cooldown timer, and in response to the cooldown timer elapsing, return the device to normal operation.

Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: Systems and methods for data anomaly detection include recommending one or more algorithms from a set of algorithms to process received time series data, wherein the one or more algorithms are recommended based at least in part on a type of workload for processing the received time series data. Assisted parameter tuning is provided for a detected anomaly alert and calibration, and the received time series data is processed based on a user selected algorithm that is parameter tuned.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Abstract: Compounds that inhibit PI3K?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3K?.